Cogent Biosciences, Inc. (COGT)
NasdaqGS
Price as at 1 Oct 2026, 01:14 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Cogent Biosciences, Inc. trades at $32.02. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
10 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$38.55M · 0.1% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$35.70M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$35.13M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$32.88M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$28.80M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in COGT
Trades in COGT disclosed by members of Congress and executive-branch officials, latest first:
- Christopher L. Jacobs · HouseBuy · $1,001 - $15,000 · traded 12 Dec 2022 · disclosed 20 Jan 2023
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own COGT?
10 of the institutions we track reported a position in COGT in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its COGT data?
Fundamentals for COGT come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 01:14 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for COGT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.